ArticleAnnals of medicine2026
The value of proteinuria for the administration of rituximab in patients with PLA2R-associated membranous nephropathy: a single-centre retrospective analysis.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveStudies have shown that the efficacy of rituximab (RTX) in patients with M-type phospholipase A2 receptor (PLA2R)-associated primary membranous nephropathy (PMN) is related to proteinuria. However, definitive evidence to guide the initiation of RTX therapy based on proteinuria excretion levels in PMN is still lacking.
methodsA total of 123 patients with PMN, confirmed by positive PLA2R staining in renal biopsy and/or serum anti-PLA2R antibody positivity, were enrolled in this study. All patients received RTX therapy. The patients were categorized into two groups based on their baseline proteinuria: 4-6 g and >6 g. Compared the outcomes and adverse events of patients between different groups after 12-month follow-up.
resultsThis study revealed statistically significant differences in composite and complete remission rates after 12-month follow-up among PMN patients with different baseline proteinuria levels following RTX treatment. At 12-month follow-up, we found that the partial remission (PR) rate in the 4-6 g group was significantly higher than that in the >6 g group at the 1st and 3rd months (
conclusionsOur findings show that lower baseline proteinuria was associated with a better response to RTX in PLA2R-associated PMN patients, whereas higher baseline proteinuria, particularly >12 g/day, was associated with lower remission rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.